These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23525758)

  • 1. Targeting the insulin-like growth factor-1 receptor in human cancer.
    Arcaro A
    Front Pharmacol; 2013; 4():30. PubMed ID: 23525758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF-IR: potential role in antitumor agents.
    Guerreiro AS; Boller D; Doepfner KT; Arcaro A
    Drug News Perspect; 2006 Jun; 19(5):261-72. PubMed ID: 16941048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
    Mitsiades CS; Mitsiades N
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.
    Liefers-Visser JAL; Meijering RAM; Reyners AKL; van der Zee AGJ; de Jong S
    Cancer Treat Rev; 2017 Nov; 60():90-99. PubMed ID: 28934637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.
    Fidler MJ; Shersher DD; Borgia JA; Bonomi P
    Ther Adv Med Oncol; 2012 Mar; 4(2):51-60. PubMed ID: 22423264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IGF-1 signaling pathways in gynecologic malignancies.
    Bruchim I; Werner H
    Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
    Ulanet DB; Ludwig DL; Kahn CR; Hanahan D
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10791-8. PubMed ID: 20457905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugging IGF-1R in cancer: New insights and emerging opportunities.
    Wang P; Mak VC; Cheung LW
    Genes Dis; 2023 Jan; 10(1):199-211. PubMed ID: 37013053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
    Rieder S; Michalski CW; Friess H; Kleeff J
    Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
    Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
    BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor.
    Zhang H; Yee D
    Expert Opin Investig Drugs; 2004 Dec; 13(12):1569-77. PubMed ID: 15566314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
    Simpson A; Petnga W; Macaulay VM; Weyer-Czernilofsky U; Bogenrieder T
    Target Oncol; 2017 Oct; 12(5):571-597. PubMed ID: 28815409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.
    Negi A; Ramarao P; Kumar R
    Mini Rev Med Chem; 2013 Apr; 13(5):653-81. PubMed ID: 23373648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.
    Jin M; Buck E; Mulvihill MJ
    Oncol Rev; 2013 Apr; 7(1):e3. PubMed ID: 25992224
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.